Related by context. All words. (Click for frequent words.) 68 imatinib therapy 67 irinotecan containing 67 Ribavirin causes 67 dasatinib Sprycel ® 66 Ph + acute lymphoblastic 66 fluoropyrimidine oxaliplatin 66 Philadelphia Chromosome Positive 66 myelodysplastic myeloproliferative diseases 66 nilotinib Tasigna ® 66 patients coinfected 66 metastatic malignant 65 dasatinib Sprycel 65 tyrosine kinase inhibitor TKI 65 K ras mutations 65 essential thrombocythemia ET 65 PEGylated Fab fragment 65 leukemia CLL 65 CML CP 65 imatinib Gleevec ® 65 chronic myeloid 65 stage IIIb IV 65 CYT# potent vascular disrupting 64 castration resistant hormone refractory 64 chronic eosinophilic leukemia 64 Gleevec resistant 64 leukemia AML 64 achieve sustained virologic 64 carcinoma mCRC 64 alkylating agents 64 recurrent glioblastoma multiforme 64 Refractory Hodgkin Lymphoma 63 cetuximab Erbitux R 63 anthracycline containing 63 imatinib resistant 63 T#I [002] 63 refractory chronic lymphocytic 63 FUSILEV enhances 63 relapsed Acute Myeloid 63 Stage IIIB IV 63 tumors GIST 63 anthracycline taxane 63 PKC# 63 5 FU leucovorin 63 hypereosinophilic syndrome 62 Myelodysplastic Syndrome MDS 62 EGFR tyrosine kinase inhibitor 62 EGFR mutation positive 62 systemic anaplastic large 62 taxane chemotherapy administered 62 PNP inhibitor 62 pulmonary Pseudomonas aeruginosa 62 ribavirin RBV 62 metastatic colorectal 62 HIV coinfected 62 erlotinib Tarceva ® 62 HLA DR4 immune 62 LymphoStat B belimumab 62 tyrosine kinase inhibitors TKIs 62 imatinib Gleevec 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 kidney urologic 62 selective modulator 61 epithelial tumors 61 ® lenalidomide 61 EGFR TKI 61 diagnosed Ph + 61 combining voreloxin 61 bone marrow reticulin deposition 61 myelogenous leukemia 61 Relapsed Refractory 61 refractory NSCLC 61 mild vasodilator 61 smoldering multiple myeloma 61 chronic granulomatous disease 61 antibody MAb 61 relapsed MM 61 Pharmacokinetics PK 61 metastatic castration resistant 61 renal failure interstitial lung 61 Aflibercept 61 phase Ph + 61 indolent follicular non 61 sunitinib Sutent 61 Chronic Myelogenous Leukemia CML 61 FOLFOX6 61 refractory colorectal cancer 61 Ph + ALL 61 humanised monoclonal antibody 61 gastrointestinal stromal tumors GISTs 61 cytotoxic therapy 61 heavily pretreated 61 colorectal cancer liver metastases 61 dexamethasone Decadron 61 sunitinib Sutent ® 61 previously untreated follicular 61 gastrointestinal stromal tumor GIST 61 myeloid metaplasia 61 metastatic pancreatic 61 cell lymphoma CTCL 60 bevacizumab Avastin R 60 BCG refractory carcinoma 60 INSPIRE Trial Phase III 60 receptor tyrosine kinase inhibitor 60 refractory indolent non 60 non mutated KRAS 60 CYP#A# substrate 60 chronic myeloid leukemia CML 60 EGFR expressing mCRC 60 anthracyclines taxanes 60 medically refractory epilepsy 60 TO AVOID PREGNANCY WHILE 60 parathyroid carcinoma 60 antiretroviral naïve 60 gefitinib Iressa 60 intravesical therapy 60 cell carcinoma RCC 60 leukemia CML 60 SNT-MC#/idebenone 60 resistant hormone refractory 60 relapsed leukemia 60 BRCA deficient 60 Annamycin 60 lumiliximab 60 castrate resistant 60 5 HT1A receptor 60 Bucindolol 60 plus prednisone prednisolone 60 Bosutinib 60 refractory chronic myeloid 60 included exfoliative dermatitis 60 cyclophosphamide methotrexate 60 atypical hemolytic uremic syndrome 60 cetuximab Erbitux ® 60 atypical Hemolytic Uremic Syndrome 60 CC genotype 60 Chronic lymphocytic leukemia CLL 60 CTEPH 60 lymphoproliferative disease 60 Naive Patients 60 multiple myeloma MM 60 small molecule tyrosine 60 refractory cutaneous T 60 novel VDA molecule 60 metastatic colorectal carcinoma 60 antibiotic methicillin 60 Achieves Primary Endpoint 60 evaluating picoplatin 60 HLA DR2 60 Severe Sepsis 60 HBeAg negative 60 pegylated interferon peg IFN 60 CYP#A# CYP#D# 60 Meets Primary Endpoint 60 Fc fusion protein 60 non splenectomized 60 familial amyloidotic polyneuropathy FAP 60 LHRH receptor positive 60 SPRYCEL ® 59 alkylating agent 59 TNF blocker therapy 59 taxane therapy 59 mitoxantrone chemotherapy 59 CTAP# Capsules 59 T#I mutation 59 PEGylated anti 59 hypermethylated 59 metaglidasen 59 de novo kidney transplant 59 Campath alemtuzumab 59 corticosteroids immunoglobulins 59 nephropathic cystinosis cystinosis 59 opioid induced constipation OIC 59 FEMALES SHOULD BE ADVISED 59 Diffuse Large B 59 xanthine oxidase inhibitor 59 5 fluorouracil leucovorin 59 hormone refractory 59 stage IIIB 59 estramustine 59 cutaneous T 59 refractory metastatic 59 Omacetaxine 59 mitoxantrone plus 59 HGS ETR1 mapatumumab 59 acetonide FA 59 decompensated liver disease 59 refractory acute myeloid 59 Atypical Hemolytic Uremic Syndrome 59 prior chemotherapy regimens 59 polycythemia vera PV 59 severe malignant osteopetrosis 59 Tyrosine Kinase Inhibitor 59 lenalidomide Revlimid R 59 bevacizumab Avastin ® 59 taxane resistant 59 response CCyR 59 polycythemia vera essential thrombocythemia 59 recurrent metastatic 59 subependymal giant cell 59 treat atopic dermatitis 59 whose tumors overexpress 59 Associated Adipose Redistribution 59 Fludarabine 59 remitting MS 59 Hodgkin lymphoma HL 59 Chronic Myeloid Leukaemia 59 ribavirin therapy 59 papillary renal cell carcinoma 59 superficial bladder cancer 59 D aspartate NMDA receptor 59 leukemia ALL 59 pyrexia mucositis sepsis febrile 59 invasive lobular carcinoma 59 KIT mutations 59 acute myeloid 59 asymptomatic metastatic 59 MAGE A3 ASCI 59 immunomodulatory therapy 59 completely resected 59 SSc 59 evaluating tivozanib 59 mTOR mammalian target 59 cardiotoxic 59 lymphomas leukemias 59 receiving immunosuppressive therapy 59 relapsed acute myelogenous 59 anti PlGF 59 metastatic hormone refractory 59 Leukemia AML 59 syngeneic 59 unresectable tumors 59 R lenalidomide 59 recurrent glioblastoma 58 ADPKD 58 nucleoside naive 58 Myelodysplastic Syndrome 58 acute humoral rejection 58 drug DMARD 58 myeloproliferative disorder 58 gastrointestinal stromal tumor 58 hepatic lipase 58 Vidaza ® 58 Anthracycline 58 Castration Resistant Prostate Cancer 58 metastatic gastric 58 lymphoid blast 58 imatinib mesylate 58 peritoneal carcinomatosis 58 BRAF V#E mutation 58 evaluating CK # 58 hypomethylating agents 58 dyskeratosis congenita 58 lamivudine resistant 58 acute GvHD 58 Temsirolimus 58 differentiated thyroid 58 steroid refractory ulcerative 58 GSTP1 58 relapsed CLL 58 situ CIS 58 vinca alkaloid 58 recurrent NSCLC 58 metastatic bladder 58 MELAS 58 castration resistant 58 Tasigna prolongs 58 CCyR 58 cyclophosphamide chemotherapy 58 Nilotinib 58 Progressive Multifocal Leukoencephalopathy 58 Chronic Myeloid Leukemia 58 secondary hyperparathyroidism 58 glutamic acid decarboxylase 58 primary humoral immunodeficiency 58 FLT3 mutations 58 prostate carcinoma 58 normal karyotype 58 castrate resistant prostate cancer 58 genotype 1b 58 beta 1a 58 chronic myelogenous leukemia CML 58 neutropenia dehydration dyspnea 58 HER2 overexpression 58 relapsing remitting MS RRMS 58 pediatric malignancies 58 primary immunodeficiency PI 58 purpura ITP 58 induced tumor regression 58 Complicated Skin 58 immunocompetent adults 58 NMIBC 58 refractory myeloma 58 mutated K ras 58 imatinib resistance 58 Letairis ambrisentan 58 discontinued Viread 58 lymphoma CTCL 58 adriamycin 58 hematopoietic cancers 58 autologous transplants 58 Ceflatonin 58 naïve HCV 58 Leukemias 58 Acute Myeloid Leukaemia AML 58 adalimumab Humira 58 trastuzumab Herceptin ® 58 liposomal formulation 58 refractory Hodgkin 58 gastrointestinal stromal tumors GIST 58 AVASTIN 58 gastrointestinal stromal tumors 57 Epratuzumab 57 M#V mutation 57 Granulocyte Colony Stimulating Factor 57 advanced metastatic renal 57 preventers known 57 ara C 57 taxane refractory 57 virologically 57 plus prednisone 57 achieved CCyR 57 investigational oral hepatitis C 57 KRAS mutant 57 acute mania 57 dalteparin 57 lymphoid malignancies 57 docetaxel Taxotere ® 57 TTR amyloidosis 57 sorafenib Nexavar 57 choroidal vasculopathy 57 anthracycline chemotherapy 57 CK # administered 57 mycophenolic acid 57 Albuferon TM 57 weekly subcutaneous injections 57 CIMZIA TM certolizumab pegol 57 ZOLINZA 57 pathophysiological effects 57 Genentech Rituxan 57 allogeneic HSCT 57 TKIs 57 beta adrenergic receptor 57 arteritis 57 Irinotecan 57 ritonavir boosted 57 Gleevec imatinib mesylate 57 systemic fungal infections 57 small molecule Hedgehog 57 Chronic Lymphocytic Leukemia CLL 57 TNF antagonist 57 BARACLUDE ® 57 demonstrated antitumor activity 57 cediranib 57 basal cell nevus syndrome 57 psoriatic arthritis PsA 57 fallopian tube carcinoma 57 Glioblastoma Multiforme GBM 57 unresectable locally advanced 57 EGFR expressing metastatic colorectal 57 neurologic progression 57 metastatic SCCHN 57 Mantle Cell Lymphoma 57 trastuzumab Herceptin R 57 recurrent GBM 57 Sudhir Agrawal D.Phil 57 pharmacologically active isomer 57 substantially excreted 57 refractory CLL 57 histologically active 57 p# deficient 57 mCRC patients 57 metastatic malignant melanoma 57 KRAS wild 57 transcriptase inhibitor NNRTI 57 blastic phase 57 elacytarabine 57 untreated chronic lymphocytic 57 relapsed ALL 57 basiliximab 57 denileukin diftitox 57 Azacitidine 57 ERBB2 57 Cutaneous T 57 RhuDex R 57 idarubicin 57 JAK2 V#F 57 refractory ovarian cancer 57 metastatic carcinoid 57 genetic lysosomal storage 57 protease inhibitor PI 57 non alcoholic steatohepatitis 57 idiopathic thrombocytopenic purpura ITP 57 Peginterferon 57 leukemia APL 57 metformin monotherapy 57 diabetic kidney 57 allogeneic bone marrow 57 Dasatinib 57 interferon gamma 1b 57 HCV RESPOND 2 57 deletion 5q 57 follicular Non Hodgkin 57 gemcitabine Gemzar ® 57 histone deacetylase HDAC inhibitor 57 Myelofibrosis 57 ALT normalization 57 KRAS mutant tumors 57 disease modifying antirheumatic 57 Safinamide 57 lung fibrosis 57 Flt3 56 EGFR expressing 56 TRIOLEX HE# APOPTONE HE# 56 prostate cancer HRPC 56 hypoxia inducible factor 56 Cytarabine 56 survivin expression 56 vWF 56 nicardipine 56 SinuNase TM 56 pegylated interferon alpha 2a 56 Romiplostim 56 pan histone deacetylase 56 Glioblastoma Multiforme 56 severe oral mucositis 56 generation purine nucleoside 56 riociguat 56 nonmetastatic 56 sorafenib tablets 56 Acute Myelogenous Leukemia AML 56 K#N 56 achieved ACR# 56 rituximab refractory 56 virus HCV protease inhibitor 56 interferon ribavirin 56 coinfected patients 56 patientswith 56 Navelbine ® 56 acadesine 56 thalidomide Thalomid 56 constitutively expressed 56 Fingolimod 56 Chronic Hepatitis C 56 R Saizen R 56 metastatic GIST 56 receiving VELCADE 56 MCyR 56 mapatumumab 56 BI/NAP#/# 56 EGFr expressing metastatic colorectal 56 gemcitabine carboplatin 56 soluble tumor necrosis 56 non constipating irritable 56 8mg/kg 56 induce remission 56 pegylated interferon alfa 2a 56 mRCC 56 CD# CD# 56 esophageal candidiasis 56 baminercept 56 Pegylated 56 CD8 + cytotoxic 56 small lymphocytic lymphoma 56 untreated metastatic melanoma 56 pan HDAC inhibitor 56 transthyretin amyloidosis 56 Pseudomonas lung 56 Kit CD# positive 56 cell acute lymphoblastic 56 Akt inhibitor 56 prostate cancer CRPC 56 IV metastatic melanoma 56 immunocompetent 56 NPM1 mutations 56 VEGF receptor inhibitor 56 LRAT 56 Elotuzumab 56 primary hypercholesterolemia 56 thetreatment 56 achieved sustained virologic 56 CD# expressing 56 antithymocyte globulin 56 taxane chemotherapy 56 CIMZIA r certolizumab pegol 56 Xanafide 56 systemic ALCL 56 nonhereditary 56 Chronic Myeloid Leukemia CML 56 immune thrombocytopenic purpura 56 Antitumor Activity 56 TTF Therapy 56 panitumumab Vectibix 56 CLL SLL 56 colon carcinoma 56 lymphocytosis 56 6 mercaptopurine 56 Acute Myelogenous Leukemia 56 Soft Tissue Sarcoma 56 autosomal dominant polycystic kidney 56 Epstein Barr Virus EBV 56 cause mesothelioma asbestosis 56 phase IIb study 56 TTR gene 56 interferon therapy 56 metastatic renal cell 56 cisplatin resistant 56 HER2/neu 56 ACTEMRA TM 56 recurrent malignant glioma 56 biliary tract cancer 56 metastatic neuroendocrine tumors 56 pegylated alpha interferon 56 infliximab monotherapy 56 TNF alpha selectively neutralizing 56 chimeric monoclonal antibody 56 liposomal doxorubicin 56 immune thrombocytopenic purpura ITP 56 Clusterin 56 hepatic metastases 56 Ph + CP 56 Bezielle 56 irinotecan chemotherapy 56 trans retinoic acid ATRA 56 adverse cytogenetics 56 vaginal candidiasis 56 vinorelbine tartrate 56 pathological hallmarks 56 phase IIb clinical 56 antiangiogenic agent 56 Maribavir 56 OMNARIS HFA 56 papillary RCC 56 assessing T DM1 56 plus dacarbazine 56 CMV infections 56 eosinophilic asthma 56 lactate dehydrogenase LDH 56 Enzyme Replacement Therapy 56 Acute Promyelocytic Leukemia 56 nilotinib 56 pretransplant 56 alfa 2a 56 drug zotarolimus 56 bleomycin 56 prostate cancer CaP 56 Trial Evaluating 56 galiximab 56 squamous cell lung cancer 56 intravenous belinostat 56 Torisel temsirolimus 56 alefacept 56 Nexavar sorafenib 56 Elvitegravir 55 remission induction 55 multiple sclerosis psoriasis 55 risperidone Risperdal 55 localized renal 55 2 methoxyestradiol 55 underwent resection 55 abacavir lamivudine 55 minimally symptomatic 55 mutated KRAS gene 55 Sprycel dasatinib 55 KRAS oncogene 55 tumor lysis syndrome 55 PegIFN 55 Ceflatonin R 55 adrenocortical cancer 55 deep venous thromboses 55 receptor blocker 55 metastatic renal cell carcinoma 55 vidofludimus 55 Doxil ® 55 imatinib mesylate Gleevec 55 interferon beta therapy 55 lymphoid tumors 55 Aplidin 55 homozygous FH 55 T2DM 55 EGFr expressing mCRC 55 metastatic castrate resistant 55 potentially hepatotoxic 55 malignant ascites 55 recurrent bladder 55 interferon alpha IFN alpha 55 castration resistant prostate cancer 55 cytogenetic responses 55 Voreloxin 55 predominantly classic subfoveal 55 hematological malignancy 55 oral prodrug 55 Occlusive Disease 55 Cell Lymphoma CTCL 55 hepatorenal syndrome 55 Improved Progression 55 erythematosus 55 non myeloid malignancies 55 thymoma 55 systolic hypertension 55 Gleevec imatinib 55 Chronic myeloid leukemia 55 FOLFOX chemotherapy 55 recurrent genital herpes 55 R sorafenib tablets 55 refractory acute promyelocytic 55 resectable 55 bendamustine 55 systemic RNAi therapeutic 55 colorectal liver metastases 55 intravenous cyclophosphamide 55 AP INVESTIGATION Blowout 55 THAT ARE DIFFICULT TO 55 Cloretazine 55 Adjuvant chemotherapy 55 Pegasys ® 55 standard chemotherapy regimens 55 vinca alkaloids 55 pulmonary hypertension PH 55 surgically resectable 55 achieved sustained virological 55 intravesical 55 chronic immune thrombocytopenic 55 atherosclerosis rheumatoid arthritis 55 lamivudine refractory patients 55 relapsed ovarian cancer 55 GISTs 55 GRN# 55 systemically administered 55 tyrosine kinase inhibitors 55 Val HeFT 55 cancer neuroendocrine tumor 55 Factor Receptor 55 cholangiocarcinoma 55 Vidaza azacitidine 55 ATTR CM 55 erythema nodosum 55 Adjunctive 55 ovarian carcinoma 55 myeloproliferative diseases 55 evaluating Prochymal 55 non metastatic osteosarcoma 55 caspofungin 55 GW# [003] 55 type KRAS 55 GRNCM1 55 mutated KRAS 55 liver decompensation 55 Carcinoid tumors 55 Daclizumab 55 chemoresistant 55 systemic invasive fungal 55 colorectal carcinoma 55 refractory CTCL 55 fibrosarcoma 55 hepatocellular carcinomas 55 Xeloda ® 55 oral JAK1 55 low ptau levels 55 novel emulsion formulation 55 Phase #b/#a clinical 55 Cholangiocarcinoma 55 murine model 55 Advanced Renal Cell 55 neurological manifestations 55 PEGINTRON TM 55 Folfox 55 AGTR1 55 multi factorial disease 55 Renal Cell Carcinoma RCC 55 chemoresistance 55 paclitaxel cisplatin 55 PEGylated interferon beta 1a 55 metastatic carcinoma 55 membranous nephritis 55 autoantibody positive 55 S6 Kinase 55 palifermin 55 refractory CML 55 Graft Versus Host 55 Alessandro Riva 55 allogeneic hematopoietic cell 55 T#I mutant 55 histone deacetylase inhibitor 55 relapsing multiple sclerosis 55 DFMO 55 acute promyelocytic leukemia 55 hypoxia induced 55 fungoides 55 Pelvic inflammatory 55 multikinase inhibitor 55 interstitial cystitis IC 55 relapsed refractory 55 haematologic 55 fistulizing Crohn disease 55 IMiDs ® compound 55 Vincristine 55 Simulect 55 pediatric Crohn disease 55 Pralatrexate 55 PC# cells 55 overexpress 55 PegIFN RBV 55 mesangial 54 non squamous histology 54 resistant ovarian cancer 54 Leber Hereditary Optic Neuropathy 54 Gel repository corticotropin injection 54 e antigen HBeAg 54 pheochromocytoma 54 papillary thyroid carcinoma 54 lymphoid cancers 54 Alemtuzumab 54 hormone LHRH antagonist 54 myelofibrosis polycythemia vera 54 Lupus Nephritis 54 refractory AML 54 pT3 54 anaplastic astrocytoma 54 BRAF mutation 54 antiproliferative effects 54 Certolizumab pegol 54 Idiopathic Pulmonary Fibrosis 54 HBeAg positive 54 Epothilone D 54 Solid Tumors criteria 54 Chronic Lymphocytic Leukemia 54 bronchial inflammation medicine 54 monocyte chemotactic protein 54 Nexavar tablets 54 selective kinase inhibitor 54 cancer mCRC 54 invasive aspergillosis 54 omega interferon 54 Sezary syndrome 54 unresectable stage 54 relapsed SCLC 54 myelodysplastic syndrome MDS 54 metastatic HRPC 54 Newly Diagnosed Multiple Myeloma 54 erlotinib Tarceva 54 Pirfenidone 54 QuantiFERON 54 Vidaza R 54 cervical lymph nodes 54 tiuxetan 54 VELCADE melphalan 54 PTPN# 54 alvespimycin 54 alpha1 antitrypsin AAT deficiency 54 idiopathic thrombocytopenic purpura 54 chemotherapy cisplatin 54 NNRTI resistant virus 54 PAOD 54 potently inhibited 54 Gorlin syndrome 54 diabetic gastroparesis 54 non splenectomised 54 non hodgkin lymphoma 54 Pulmonary hypertension 54 certolizumab 54 hA# 54 detectable HCV RNA 54 Gefitinib 54 unresectable recurrent 54 androgen independent 54 RhuDex TM 54 small molecule activators 54 BCR ABL mutation 54 chronic myocardial ischemia 54 Femara letrozole 54 Aptivus ® 54 relapsed acute lymphoblastic 54 AGILECT R 54 Morquio 54 5q deletion 54 Gleevec Glivec 54 oral squamous cell 54 myeloid 54 pegylated 54 transplanted islets 54 XL# inhibits 54 Papillary 54 idiopathic myelofibrosis 54 protein kinase inhibitor 54 pancreatic neuroendocrine tumors 54 refractory peripheral T 54 catheter occlusion 54 mutated p# 54 IGF 1R inhibitor 54 BRAF V# mutation 54 progressive PsA 54 doxorubicin cyclophosphamide 54 pertuzumab 54 vancomycin resistant Staphylococcus aureus 54 fludarabine 54 pancreatic adenocarcinoma 54 Relapsing remitting MS 54 forodesine 54 complement inhibitor eculizumab 54 undergoing hematopoietic stem 54 LHRH analogues 54 invasive lobular 54 relapsed AML 54 oxaliplatin Eloxatin 54 administered subcutaneously 54 anti leukemic 54 fosbretabulin 54 pegylated liposomal doxorubicin 54 advanced carcinoid 54 visceral metastases 54 melphalan prednisone 54 relapsed refractory multiple myeloma 54 leukemic stem cells 54 olaparib 54 Bordetella pertussis 54 gemcitabine Gemzar 54 Bronchiectasis 54 FGFR4 54 mTOR inhibitors 54 doxorubicin Adriamycin 54 Angiotensin II 54 microbiologically evaluable 54 docetaxel chemotherapy 54 BRAF mutations 54 hepatocellular 54 alveolar rhabdomyosarcoma 54 neuroendocrine cancers 54 INCB# [003] 54 Pemetrexed 54 B CLL 54 Panzem NCD 54 Lambert Eaton Myasthenic 54 BCR ABL inhibitor 54 locoregional recurrence 54 MyVax R 54 infliximab therapy 54 Severe acute exacerbations 54 transplantation HCT 54 leukemia multiple myeloma 54 K RAS 54 Follicular Lymphoma 54 vemurafenib 54 relapsed multiple myeloma 54 LRP5 54 docetaxel Taxotere R 54 uric acid lowering 54 mucinous 54 HIV coinfection 54 cisplatin gemcitabine 54 dilated cardiomyopathy DCM 54 antiepileptic medications 54 TRO# 54 allogeneic hematopoietic stem cell 54 standard chemotherapy regimen 54 pulmonary exacerbations 54 methotrexate therapy 54 Tyrosine Kinase Inhibitors 54 interleukin IL -# 54 CD#c 54 mutant KRAS 54 hematological parameters 54 vismodegib 54 dasatinib 54 streptococcal toxic 54 curative resection 54 fallopian tube cancers 54 stage IIIB IV 54 prior chemotherapy regimen 54 paraganglioma 54 paclitaxel Taxol 54 nutlin 3a 54 alkaline phosphatase ALP 54 Nucleoside 54 neuro degenerative 54 Lenalidomide 54 bladder carcinoma 54 MGd 54 immunomodulatory agents 54 Arsenic trioxide 54 zoledronic acid Reclast 54 expressing metastatic colorectal 54 PsA 54 interferon alfa 2b 54 Hepsera adefovir dipivoxil 54 activating mutations 54 unresectable 54 motesanib 54 RRM1 54 mg/m2 administered 54 Immunosuppressive 54 retinal ischemia 54 primidone 54 PD LID 54 Xelox 54 carcinoma HCC 54 dacarbazine DTIC 54 advanced epithelial ovarian 54 progressive neurodegenerative disorder 54 CIMZIA ™ 54 Idiopathic pulmonary fibrosis 54 HCV genotype 1 54 folinic acid 54 Pegylated Interferon 54 Related Anemia 54 Vinorelbine 53 venlafaxine XR 53 Hypoxia Inducible Factor 53 muscular dystrophy cystic fibrosis 53 haematologic malignancies 53 patients receiving myelosuppressive 53 pegylated interferons 53 anthracycline therapy 53 Laquinimod 53 adjuvant GIST 53 IgG1 monoclonal antibody 53 chronic HCV genotype 53 HNSCC 53 TNF inhibitor 53 radiotherapy RT 53 dirucotide MBP# 53 myeloproliferative neoplasms 53 inhibit oxidative stress 53 Telintra 53 ELACYT 53 malignant pleural effusion 53 Nonalcoholic fatty liver 53 refractory gastrointestinal stromal 53 IV NSCLC 53 epithelioid 53 pegylated interferon alpha 53 HLA DR4 53 known sulfonamide allergy 53 calcineurin inhibitor 53 Variant Creutzfeldt Jakob Disease 53 MAGE A3 53 dosed orally 53 non metastatic resectable 53 HBeAg 53 Everolimus 53 heterozygotes 53 obstructive coronary artery 53 HIF 1alpha 53 Phase IIb trials 53 Mitomycin C 53 plasmid encoding 53 haematopoietic 53 constitutively active 53 cytarabine daunorubicin 53 Surgical resection 53 Rituxan rituximab 53 acute decompensated heart 53 underwent surgical resection 53 Platinol ® cisplatin 53 follicular lymphomas 53 myelofibrosis MF 53 post transplant lymphoproliferative 53 null responder HCV 53 receptor inhibitor 53 plasma pharmacokinetics 53 corticotropin injection 53 metastatic kidney 53 bortezomib refractory 53 FLT3 ITD 53 Li Fraumeni Syndrome 53 progressive psoriatic arthritis 53 follicular lymphoma FL 53 malignancy HCM 53 abacavir Ziagen 53 HBV HCV 53 heavily pretreated patients 53 Glioblastoma multiforme GBM 53 immunosuppressant drug 53 TMC# C# 53 cMET 53 hematologic disorders 53 drugs DMARDs 53 ABCB1 53 advanced unresectable 53 Acute Myeloid Leukaemia 53 psoriasis inflammatory bowel 53 BCG refractory 53 Interferon Beta 53 dopamine partial agonist 53 lupus scleroderma 53 Waldenstrom macroglobulinemia 53 FasL 53 splenectomized 53 Arranon 53 oral rivaroxaban 53 diastolic heart 53 asthenia fatigue 53 LHON 53 progression TTP 53 Quinamed 53 Acute myeloid leukemia 53 radiation sensitizer 53 Chronic lymphocytic leukemia 53 imatinib 53 Degarelix